RCT | Befotertinib tops Icotinib in NSCLC progression-free survival, but increases serious adverse events
6 Jun, 2023 | 14:13h | UTCBefotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)